Abstract
In this study, the enteric-coated delayed-release pellets of duloxetine hydrochloride (DLX) were formulated using a fluidized bed coater. Three separate layers, the drug layer, the barrier layer, and the enteric layer, were coated onto inert core pellets. Among the three formulations (F1–F3), the dissolution profiles of formulation F2 were most similar to those of the marketed product, with similarity and difference factors of 83.99 and 3.77, respectively. In addition, pharmacokinetic parameters of AUC, Cmax, Tmax, t1/2, Kel, and MRT of DLX for the developed formulation (F2) did not differ significantly from those for the marketed product in beagle dogs, suggesting that they were bioequivalent. Our results demonstrated that the in vitro dissolution data resembled the in vivo performance of the drug. Therefore, this study has a positive scope for further scale up and development of the formulation for achievement of the generic product.
Similar content being viewed by others
References
Abdul, S., A.V. Chandewar, and S.B. Jaiswal. 2010. A flexible technology for modified-release drugs: Multiple-unit pellet system (MUPS). Journal of Controlled Release 147: 2–16.
Bymaster, F.P., L.J. Dreshfield-Ahmad, P.G. Threlkeld, J.L. Shaw, L. Thompson, D.L. Nelson, S.K. Hemrick-Luecke, and D.T. Wong. 2001. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25: 871–880.
Cao, Q.R., J.S. Choi, Y. Liu, W.J. Xu, M. Yang, B.J. Lee, and J.H. Cui. 2013. A formulation approach for development of HPMC-based sustained release tablets for tolterodine tartrate with a low release variation. Drug Development and Industrial Pharmacy 39: 1720–1730.
Chatlapalli, R., and B.D. Rohera. 1998. Physical characterization of HPMC and HEC and investigation of their use as pelletization aids. International Journal of Pharmaceutics 161: 179–193.
Choi, H., Y. Oh, and C. Kim. 1998. In situ gelling and mucoadhesive liquid suppository containing acetaminophen: enhanced bioavailability. International Journal of Pharmaceutics 165: 23–32.
Costa, P., J.M. Sousa Lobo, M.C. Gohel, and M.K. Panchal. 2001. Modeling and comparison of dissolution profiles. European Journal of Pharmaceutical Sciences 13: 123–133.
Costa, P., and J.M. Sousa Lobo. 2001. Influence of dissolution medium agitation on release profiles of sustained-release tablets. Drug Development and Industrial Pharmacy 27: 811–817.
Fishbain, D.A., J. Hall, A.L. Meyers, J. Gonzales, and C. Mallinckrodt. 2008. Does pain mediate the pain interference with sleep problem in chronic pain? Findings from the studies for management of diabetic peripheral neuropathic pain with duloxetine. Journal of Pain and Symptom Management 36: 639–647.
Frohoff-Hulsmann, M.A., B.C. Lippold, and J.W. McGinity. 1999. Aqueous ethyl cellulose dispersion containing plasticizers of different water solubility and hydroxy propyl methyl-cellulose as coating material for diffusion pellets II: properties of sprayed films. European Journal of Pharmaceutics and Biopharmaceutics 48: 67–75.
Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics, 2nd ed. New York: Marcel Dekker.
Goldstein, D.J., Y. Lu, M.J. Detke, C. Wiltse, C. Mallinckrodt, and M.A. Demitrack. 2004. Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine. Journal of Clinical Psychopharmacology 24: 389–399.
Goyanes, A., and R. Martinez-Pacheco. 2013. New co-processed MCC-based excipient for fast release of low solubility drugs from pellets prepared by extrusion-spheronization. Drug Development and Industrial Pharmacy (Early online:1–7).
Hausner, H.H. 1967. Friction conditions in a mass of metal powder. International Journal of Powder Metallurgy 3: 7–13.
International Conference on Harmonization (ICH Q2A, Q2B), 1995. Guidelines on validation of analytical procedures.
Jansen, P.J., P.L. Oren, C.A. Kemp, S.R. Maple, and S.W. Beartschi. 1998. Characterization of impurities formed by interaction of duloxetine HCl with enteric polymers hydroxypropyl methylcellulose acetate duccinate and hydroxypropyl methylcellulose phthalate. Journal of Pharmaceutical Sciences 87: 81–85.
Korakianiti, E.S., D.M. Rekkas, P.P. Dallas, and N.H. Choulis. 2000. Optimization of the pelletization process in a fluid- bed rotor granulator using experimental design. AAPS Pharm SciTech 1: 71–75.
Lecomte, F., J. Siepmann, M. Walther, R.J. MacRae, and R. Bodmeier. 2004. Polymer blends used for the coating of multiparticulates: Comparison of aqueous and organic coating techniques. Pharmaceutical Research 21: 882–890.
Mastan, S., T.B. Latha, and S. Ajay. 2011. The basic regulatory considerations and prospects for conducting bioavailability/bioequivalence (BA/BE) studies—An overview. Comparative Effectiveness Research 1: 1–25.
Mease, P.J., I.J. Russell, D.K. Kajdasz, C.G. Wiltse, M.J. Detke, M.M. Wohlreich, D.J. Walker, and A.S. Chappell. 2010. Long term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Seminars in Arthritis and Rheumatism 39: 454–464.
Mohamed, F.A., M. Roberts, L. Seton, J.L. Ford, M. Levina, and A.R. Rajabi-Siahboomi. 2013. The influence of HPMC concentration on release of theophylline or hydrocortisone from extended release mini-tablets. Drug Development and Industrial Pharmacy 38: 1167–1174.
Robinson, D., and L. Cardozo. 2010. New drug treatments for urinary incontinence. Maturitas 65: 340–347.
Sharma, A., M.J. Goldberg, and B.J. Cerimele. 2000. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. The Journal of Clinical Pharmacology 40: 161–167.
Shravani, D., P.K. Lakshmi, and J. Balasubramaniam. 2011. Preparation and optimization of various parameters of enteric coated pellets using the Taguchi L9 orthogonal array design and their characterization. Acta Pharmaceutica Sinica B 1: 56–63.
Sinha, V.R., R. Kumria, and J.R. Bhinge. 2009. Stress degradation studies on duloxetine hydrochloride and development of an RP-HPLC method for its determination in capsule formulation. Journal of Chromatographic Science 47: 589–593.
Valizadeh, H., P. Nayyeri-Maleki, S. Ghanbarzadeh, A. Sheikhloo, H. Servat, M. Nemati, and P. Zakeri-Milani. 2014. Pharmacokinetics and bioequivalence of two brands of metformin 500 mg tablets in Iranian healthy volunteers. Journal of Pharmaceutical Investigation 44: 61–68.
Westanmo, A.D., J. Gayken, and R. Haight. 2005. Duloxetine: A balanced and selective norepinephrine-and serotonin-reuptake inhibitor. American Journal of Health-System Pharmacy 62: 2481–2490.
Yong, C.S., D.X. Li, D.H. Oh, J.A. Kim, B.K. Yoo, J.S. Woo, J.D. Rhee, and H.G. Choi. 2005. Retarded dissolution of ibuprofen in gelatin microcapsule by cross-linking with glutaraldehyde. Archives of Pharmacal Research 29: 431–534.
Yuksel, N., A.E. Kanik, and T. Baykara. 2000. Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and independent methods. International Journal of Pharmaceutics 209: 57–67.
Zhao, R.K., G. Cheng, J. Tang, J. Song, and W.X. Peng. 2009. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: A randomized, open-label, single- and multiple-dose study. Clinical Therapeutics 31: 1022–1036.
Acknowledgments
This study was supported by a grant from the Medical Cluster R&D Support Project of Daegu Gyeongbuk Medical Innovation Foundation, Republic of Korea (2013) (No. HT13C0011).
Author information
Authors and Affiliations
Corresponding authors
Additional information
Yong-Il Kim and Roshan Pradhan contributed equally to this study.
Rights and permissions
About this article
Cite this article
Kim, YI., Pradhan, R., Paudel, B.K. et al. Preparation and evaluation of enteric-coated delayed-release pellets of duloxetine hydrochloride using a fluidized bed coater. Arch. Pharm. Res. 38, 2163–2171 (2015). https://doi.org/10.1007/s12272-015-0590-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-015-0590-y